Patents by Inventor Lawrence McGee

Lawrence McGee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20110319378
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: June 3, 2011
    Publication date: December 29, 2011
    Applicant: AMGEN INC.
    Inventors: Michael David BARTBERGER, Ana GONZALEZ BUENROSTRO, Hilary Plake BECK, Xiaoqi CHEN, Richard Victor CONNORS, Jeffrey DEIGNAN, Jason DUQUETTE, John EKSTEROWICZ, Benjamin FISHER, Brian Matthew FOX, Jiasheng FU, Zice FU, Felix GONZALEZ LOPEZ DE TURISO, Michael GRIBBLE, JR., Darin James GUSTIN, Julie Anne HEATH, Xin HUANG, Xianyun JIAO, Michael G. JOHNSON, Frank KAYSER, David John KOPECKY, Sujen LAI, Yihong LI, Zhihong LI, Jiwen LIU, Jonathan Dante LOW, Brian Stuart LUCAS, Zhihua MA, Lawrence McGEE, Joel McINTOSH, Dustin McMINN, Julio Cesar MEDINA, Jeffrey Thomas MIHALIC, Steven Howard Olson, Yosup REW, Philip Marley ROVETO, Daqing SUN, Xiaodong WANG, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU
  • Salts and polymorphs of a potent antidiabetic compound
    Publication number: 20070293536
    Abstract: Salts and polymorphs of a compound useful in the treatment of inflammatory and metabolic conditions and diseases are provided herein. In particular, the invention provides salts and polymorphs of a compound which modulates the expression and/or function of a peroxisome proliferator-activated receptor. The salts and polymorphs are useful for the treatment or prevention of conditions and disorders associated with energy homeostasis such as type II diabetes, lipid metabolism, adipocyte differentiation and inflammation.
    Type: Application
    Filed: May 24, 2007
    Publication date: December 20, 2007
    Inventors: Henry Kruk, Lawrence McGee, Bing Yang
  • Bisaryl-sulfonamides
    Publication number: 20060084802
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR? or PPAR?. In particular, the compounds of the invention modulate the function of PPAR? or PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Application
    Filed: August 11, 2005
    Publication date: April 20, 2006
    Inventors: Philippe Bergeron, Christopher Farthing, Stuart Jones, John Liebeschuetz, Sarah Lively, Lawrence McGee, Sharon McKendry, David Sheppard, Stephen Young
  • Salts and polymorphs of a potent antidiabetic compound
    Publication number: 20050143416
    Abstract: Salts and polymorphs of a compound useful in the treatment of inflammatory and metabolic conditions and diseases are provided herein. In particular, the invention provides salts and polymorphs of a compound which modulates the expression and/or function of a peroxisome proliferator-activated receptor. The salts and polymorphs are useful for the treatment or prevention of conditions and disorders associated with energy homeostasis such as type II diabetes, lipid metabolism, adipocyte differentiation and inflammation.
    Type: Application
    Filed: October 1, 2004
    Publication date: June 30, 2005
    Inventors: Henry Kruk, Lawrence McGee, Bing Yang
  • Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor
    Patent number: 5674863
    Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: October 7, 1997
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
  • Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a
    Patent number: 5674865
    Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: October 7, 1997
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
  • Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor
    Patent number: 5663166
    Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: September 2, 1997
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
  • Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor
    Patent number: 5565449
    Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: October 15, 1996
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
  • Nonpeptidyl platelet aggregation inhibitors having specificity for the GPII.sub.b III.sub. receptor
    Patent number: 5250679
    Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: April 10, 1992
    Date of Patent: October 5, 1993
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Robert McDowell, Thomas Gadek, Peter Barker, Lawrence McGee, Rob Webb
  • Furnace electrode clamps
    Patent number: 4323717
    Abstract: A furnace electrode clamp comprises a metallic body portion (3), an electrically insulated U-shaped band (7) mounted for movement about the body and adapted to embrace the electrode (8) and at least one (preferably two) electrode contact piece(s) (13) mounted on the body and against which the electrode is clamped by the band. The or each contact piece is made from highly conductive material and is water-cooled. The small surface over which contact is made enables a high force/unit area to be established at the contact/electrode interface than hitherto and the direct water cooling facility enables higher current densities to be withstood.
    Type: Grant
    Filed: June 25, 1980
    Date of Patent: April 6, 1982
    Assignee: British Steel Corporation
    Inventors: Henry C. Garner, Lawrence McGee
  • Table
    Patent number: D436467
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: January 23, 2001
    Assignee: La-Z-Boy Incorporated
    Inventor: Lawrence McGee
  • Furniture seat
    Patent number: D498938
    Type: Grant
    Filed: October 11, 1998
    Date of Patent: November 30, 2004
    Assignee: Kingsley-Bate Co. Ltd.
    Inventors: Clay Kingsley, Chris Kingsley, Lawrence McGee